https://www.selleckchem.com/pr....oducts/pf-07265807.h
Lyme disease (LD) is an increasing public health problem. Current laboratory testing is insensitive in early infection, the stage at which appropriate treatment is most effective in preventing disease sequela. The Lyme Disease Biobank (LD collects samples from individuals with symptoms consistent with early LD presenting with or without erythema migrans (EM) or an annular, expanding skin lesion, and uninfected individuals from endemic areas. Samples were collected from 550 participants (298 cases and 252 controls) according to IRB
Synes godt om
Kommentar
Del
